(E)-2-(4-chlorobenzoyl)-3-[4-(2-phenylethynyl)phenyl]prop-2-enenitrile

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-2-(4-chlorobenzoyl)-3-[4-(2-phenylethynyl)phenyl]prop-2-enenitrile
• 化学式: C₂₄H₁₄ClNO
• 分子量: 367.8
• InChiKey: JOEQTAQEBCNCQH-CJLVFECKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• RESIN COMPOSITION AND MOLDING THEREOF
  申请人：MITSUBISHI PLASTICS, INC.

  公开号：EP1795561A1

  公开（公告）日：2007-06-13

  A resin composition comprising 100 parts by mass of lactic acid resin (A), 50 to 100 parts by mass of metal hydroxide (B) and 0.1 to 30 parts by mass of fiber (C), wherein the fiber (C) is a natural fiber or/and a fiber derived from natural material. Moldings thereof satisfy the V-0 standard or VTM-0 standard according to UL94 vertical flame test (UL94V, UL94VTM).

  一种树脂组合物，由 100 重量份的乳酸树脂 (A)、50 至 100 重量份的氢氧化金属 (B) 和 0.1 至 30 重量份的纤维 (C) 组成，其中纤维 (C) 是天然纤维或/和从天然材料中提取的纤维。根据 UL94 垂直燃烧测试（UL94V、UL94VTM），其成型品符合 V-0 标准或 VTM-0 标准。
• NOGO RECEPTOR BINDING SMALL MOLECULES TO PROMOTE AXONAL GROWTH
  申请人：Yale University

  公开号：EP2220499A2

  公开（公告）日：2010-08-25
• POLYLACTIC ACID COMPOSITES WITH NATURAL FIBERS
  申请人：INEOS Styrolution Group GmbH

  公开号：EP3183288A1

  公开（公告）日：2017-06-28
• Resin Composition And Molding Thereof
  申请人：Tanaka Kazuya

  公开号：US20070203287A1

  公开（公告）日：2007-08-30

  A resin composition comprising 100 parts by mass of lactic acid resin (A), 50 to 100 parts by mass of metal hydroxide (B) and 0.1 to 30 parts by mass of fiber (C), wherein the fiber (C) is a natural fiber or/and a fiber derived from natural material. Moldings thereof satisfy the V-0 standard or VTM-0 standard according to UL94 vertical flame test (UL94V, UL94VTM).
• Nogo Receptor Binding Small Molecules to Promote Axonal Growth
  申请人：Strittmatter Stephen M.

  公开号：US20110065715A1

  公开（公告）日：2011-03-17

  The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the interaction of Nogo and Nogo receptor (NgR), the use of such compounds and compositions in the treatment or amelioration of conditions diseases or disorders, such as spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, ALS, Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, Schizophrenia or schizoaffective disorders.